# Sephience™ (sepiapterin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sepiapterin

> The FDA approved Sephience™ (sepiapterin), sponsored by PTC THERAPEUTICS, INC. (PTCT), on July 28, 2025 for children and adults living with PKU.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Sephience™ (sepiapterin) FDA approved?

Yes. The FDA approved Sephience™ (sepiapterin), sponsored by PTC THERAPEUTICS, INC. (PTCT), on July 28, 2025 for children and adults living with PKU. SEC Form 8-K: "On July 28, 2025, PTC Therapeutics, Inc. (the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria ("PKU")." [Calendar and source filings](https://sec-api.dev/pdufa/sepiapterin)

Source: SEC Form 8-K, accession 0001558370-25-009663, https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/pdufa/sepiapterin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Sephience™ (sepiapterin) |
| Codes | PTC923 |
| Sponsor | PTC THERAPEUTICS, INC. (PTCT) https://sec-api.dev/companies/ptct/catalysts |
| Indications | and adult patients with pku, children and adults living with pku, children and adults living with phenylketonuria, children and adults, Phenylketonuria |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jul 2024: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: and adult patients with PKU.
- First seen 2025-02-27, last confirmed 2025-05-06.
- SEC Form 10-Q (accession 0001070081-25-000019): "In July 2024 the Company submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000019/tmb-20250331x10q.htm
- SEC Form 10-Q (accession 0001070081-25-000019): "In July 2024, we submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000019/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001070081-25-000012): "In July 2024, we submitted a new drug application, or NDA, to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm
- SEC Form 10-K (accession 0001070081-25-000012): "In July 2024, we submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm
- SEC Form 10-K (accession 0001070081-25-000012): "In July 2024 the Company submitted an NDA to the FDA for sepiapterin for the treatment of pediatric and adult patients with PKU, including the full spectrum of ages and disease subtypes, in the United States." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm

### July 28, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: children and adults living with PKU.
- First seen 2025-07-28, last confirmed 2026-05-07.
- SEC Form 8-K (accession 0001558370-25-009663): "On July 28, 2025, PTC Therapeutics, Inc. (the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria ("PKU")." https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009663): "WARREN, N.J., July 28, 2025 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU)." https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-009663): "PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)" https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728xex99d1.htm
- SEC Form 10-Q (accession 0001070081-26-000012): "Pursuant to the Censa Merger Agreement, in July 2025, a $32.5 million milestone payment from the Company to the former Censa securityholders was triggered when the FDA approved Sephience for the treatment of children and adults living with PKU." https://www.sec.gov/Archives/edgar/data/1070081/000107008126000012/tmb-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-017575): "Pursuant to the Censa Merger Agreement, in July 2025, a $32.5 million milestone payment from the Company to the former Censa securityholders was triggered when the FDA approved Sephience for the treatment of children and adults living with PKU." https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-017575): "Pursuant to the Censa Merger Agreement, in July 2025, a $32.5 million milestone payment from the Company to the former Censa securityholders was triggered when the FDA approved Sephience for the treatment of children and adults" https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/tmb-20251231x10k.htm
- SEC Form 10-Q (accession 0001070081-25-000028): "Pursuant to the Censa Merger Agreement, in July 2025, a $32.5 million milestone from the Company to the former Censa securityholders was triggered when the FDA approved Sephience for the treatment of children and adults living with PKU." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000028/tmb-20250930x10q.htm

### July 29, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-13, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0001070081-25-000018): "- Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date -" https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001070081-25-000007): "o Sepiapterin for children and adults with PKU, accepted with an FDA action date of July 29, 2025." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000007/tmb-20250113xex99d1.htm
- SEC Form 10-Q (accession 0001070081-25-000019): "In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000019/tmb-20250331x10q.htm
- SEC Form 10-K (accession 0001070081-25-000012): "In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025." https://www.sec.gov/Archives/edgar/data/1070081/000107008125000012/tmb-20241231x10k.htm
- SEC Form 8-K (accession 0001558370-25-009663): "On July 28, 2025, PTC Therapeutics, Inc. (the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria ("PKU")." https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm

### July 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Phenylketonuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05166161 (A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor PTC Therapeutics." https://clinicaltrials.gov/study/NCT05166161

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sepiapterin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sephience™ (sepiapterin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sepiapterin

```bibtex
@misc{secapidev_pdufa_sepiapterin_20261116,
  title        = {Sephience™ (sepiapterin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sepiapterin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sepiapterin_20261116","title":"Sephience™ (sepiapterin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sepiapterin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
